The most powerful AI the US banned last month is back — and biomedical labs want it.

Run time: 5:33

In today's episode:

1. US lifts export ban; Fable 5, Mythos 5 back worldwide
2. Anthropic launches Claude Science for pharma research
3. Claude Sonnet 5 ships: near-Opus quality, cheaper
4. FDA clears on-premise brain-tumor MRI AI (Cercare)
5. GE HealthCare clears auto-contouring for radiation therapy
6. Feds reprimand AI Medicare prior-auth pilot (WISeR)
7. Qualified Health raises $125M for hospital AI
8. NVIDIA's surgical robotics foundation models advance

TL;DR:

• The US reversed its June 12 export ban: Anthropic's Fable 5 and Mythos 5 are back worldwide as of July 1 with a new safety classifier — restoring the drug-design model biomedical labs relied on. Access restored, not efficacy proven.
• Anthropic doubled down on medicine the same week: Claude Science (a research workbench aimed at pharma) and Claude Sonnet 5 (near-Opus quality at $2/$10 per Mtok) both launched June 30.
• Two FDA imaging clearances (Cercare's on-premise brain-tumor segmentation; GE's radiation-therapy auto-contouring) and one federal reprimand of an AI Medicare prior-auth contractor round out the week — capability moving forward, oversight catching up.

Sources cited:

• Al Jazeera
• STAT
• AuntMinnie
• AuntMinnie
• KUOW
• Fierce Healthcare
• Anthropic
• Axios
• NVIDIA / Hugging Face

Subscribe: YouTube

medAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.